Piramal Pharma Solutions Expands U.S. ADC Manufacturing with New Michigan Payload-Linker Suite 

Major Investment Strengthens Drug Development Capabilities 

Piramal Pharma Solutions (PPS), the contract development and manufacturing arm of Piramal Pharma Limited, has launched a new payload-linker development and manufacturing suite at its Riverview, Michigan, facility. The advanced unit is part of the company’s previously announced 90 million dollar investment program aimed at strengthening U.S.-based pharmaceutical manufacturing and development capabilities. 

The expansion also includes technology upgrades and enhanced commercial-scale sterile injectable manufacturing operations at PPS’s Lexington, Kentucky site. According to the company, these investments are designed to accelerate the delivery of innovative therapies while improving supply chain security and manufacturing efficiency for global pharmaceutical partners. 

According to Towards Healthcare, the pharmaceutical CXO market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 416.65 billion in 2026 to approximately USD 897.48 billion by 2035, representing a compound annual growth rate (CAGR) of 8.9% from 2026 to 2035. Rising demand for biopharmaceutical production, advanced drug delivery systems, automation technologies, precision dosing equipment, and increasing pharmaceutical manufacturing activities worldwide are expected to drive sustained market expansion during the forecast period. 

Advanced Facility to Support ADC and Bioconjugate Therapies 

The newly opened Riverview suite will focus on payload-linker development and manufacturing for antibody-drug conjugates (ADCs) and other complex bioconjugate therapies. Equipped with advanced automation, containment systems, and analytical technologies, the facility is expected to support seamless scaling of payload-linker programs from development through commercial production. 

Peter DeYoung, CEO of Piramal Global Pharma, said the investment reinforces the company’s commitment to U.S.-based innovation and manufacturing. He added that the new suite will help customers accelerate the development and commercialization of life-changing medicines, including ADC therapies. 

Strengthening PPS’s Integrated ADC Platform 

The Riverview facility has more than six decades of experience in drug substance development and manufacturing and provides services for active pharmaceutical ingredients and highly potent APIs. The site also plays a central role in ADCelerate™, PPS’s integrated platform designed to speed phase one ADC development. 

PPS believes the new expansion will strengthen its position as a preferred partner for pharmaceutical innovators seeking end-to-end drug development and manufacturing solutions. 

Piramal Pharma Solutions operates through a global network spanning North America, Europe, and Asia, offering services ranging from drug discovery and clinical trial supplies to biologics, vaccines, gene therapies, sterile fill-finish, and potent oral products. The company currently supports customers across more than one hundred countries worldwide. 

A recent report by Towards Healthcare highlights that the pharmaceutical CXO market is witnessing strong momentum due to growing investments in pharmaceutical manufacturing infrastructure, increasing adoption of high-purity processing systems, and rising demand for efficient fluid handling solutions across research, production, and drug development applications globally.